AWM
BPMC

Avitas Wealth Management’s Blueprint Medicines BPMC Stock Holding History

Avitas Wealth Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-31,845
Closed -$2.34M – 170
2019
Q3 		$2.34M Buy
31,845
+9,412
+42% +$814K 0.65% 71
2019
Q2 		$2.12M Buy
+22,433
New +$1.85M 0.59% 79

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Avitas Wealth Management's BPMC Position: Q4 2019 in Review

Avitas Wealth Management sold out of Blueprint Medicines (BPMC) in Q4 2019, closing a stake of 31,845 shares — an estimated $2.34M sold.

Avitas Wealth Management first reported a position in BPMC in Q2 2019 and held it in 2 quarters. The position peaked at $2.34M in Q3 2019. 227 funds tracked by Wall St. Rank hold BPMC as of Q4 2019.

  • Avitas Wealth Management reported no remaining Blueprint Medicines position as of Q4 2019 after selling out during the quarter.
  • Avitas Wealth Management sold 31,845 Blueprint Medicines shares in Q4 2019, an estimated $2.34M.
  • Avitas Wealth Management first reported a position in Blueprint Medicines in Q2 2019 and held it in 2 quarters.
  • Avitas Wealth Management's Blueprint Medicines position peaked at $2.34M in Q3 2019.
  • 227 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2019.

Based on Avitas Wealth Management's 13F filing for Q4 2019, filed 13 Feb 2020.